TY - JOUR
T1 - High-Frequency Oscillations in the Pallidum
T2 - A Pathophysiological Biomarker in Parkinson's Disease?
AU - Johnson, Luke A.
AU - Aman, Joshua E.
AU - Yu, Ying
AU - Escobar Sanabria, David
AU - Wang, Jing
AU - Hill, Meghan
AU - Dharnipragada, Rajiv
AU - Patriat, Remi
AU - Fiecas, Mark
AU - Li, Laura
AU - Schrock, Lauren E
AU - Cooper, Scott E.
AU - Johnson, Matthew D.
AU - Park, Michael C.
AU - Harel, Noam
AU - Vitek, Jerrold L.
N1 - Publisher Copyright:
© 2021 International Parkinson and Movement Disorder Society
PY - 2021/6
Y1 - 2021/6
N2 - Background: Abnormal oscillatory neural activity in the beta-frequency band (13–35 Hz) is thought to play a role in Parkinson's disease (PD); however, increasing evidence points to alterations in high-frequency ranges (>100 Hz) also having pathophysiological relevance. Objectives: Studies have found that power in subthalamic nucleus (STN) high-frequency oscillations is increased with dopaminergic medication and during voluntary movements, implicating these brain rhythms in normal basal ganglia function. The objective of this study was to investigate whether similar signaling occurs in the internal globus pallidus (GPi), a nucleus increasingly used as a target for deep brain stimulation (DBS) for PD. Methods: Spontaneous and movement-related GPi field potentials were recorded from DBS leads in 5 externalized PD patients on and off dopaminergic medication, as well as from 3 rhesus monkeys before and after the induction of parkinsonism with the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. Results: In the parkinsonian condition, we identified a prominent oscillatory peak centered at 200–300 Hz that increased during movement. In patients the magnitude of high-frequency oscillation modulation was negatively correlated with bradykinesia. In monkeys, high-frequency oscillations were mostly absent in the naive condition but emerged after the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. In patients, spontaneous high-frequency oscillations were significantly attenuated on-medication. Conclusions: Our findings provide evidence in support of the hypothesis that exaggerated, movement-modulated high-frequency oscillations in the GPi are pathophysiological features of PD. These findings suggest that the functional role(s) of high-frequency oscillations may differ between the STN and GPi and motivate additional investigations into their relationship to motor control in normal and diseased states.
AB - Background: Abnormal oscillatory neural activity in the beta-frequency band (13–35 Hz) is thought to play a role in Parkinson's disease (PD); however, increasing evidence points to alterations in high-frequency ranges (>100 Hz) also having pathophysiological relevance. Objectives: Studies have found that power in subthalamic nucleus (STN) high-frequency oscillations is increased with dopaminergic medication and during voluntary movements, implicating these brain rhythms in normal basal ganglia function. The objective of this study was to investigate whether similar signaling occurs in the internal globus pallidus (GPi), a nucleus increasingly used as a target for deep brain stimulation (DBS) for PD. Methods: Spontaneous and movement-related GPi field potentials were recorded from DBS leads in 5 externalized PD patients on and off dopaminergic medication, as well as from 3 rhesus monkeys before and after the induction of parkinsonism with the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. Results: In the parkinsonian condition, we identified a prominent oscillatory peak centered at 200–300 Hz that increased during movement. In patients the magnitude of high-frequency oscillation modulation was negatively correlated with bradykinesia. In monkeys, high-frequency oscillations were mostly absent in the naive condition but emerged after the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. In patients, spontaneous high-frequency oscillations were significantly attenuated on-medication. Conclusions: Our findings provide evidence in support of the hypothesis that exaggerated, movement-modulated high-frequency oscillations in the GPi are pathophysiological features of PD. These findings suggest that the functional role(s) of high-frequency oscillations may differ between the STN and GPi and motivate additional investigations into their relationship to motor control in normal and diseased states.
KW - Parkinson's disease
KW - deep brain stimulation
KW - high-frequency oscillations
KW - internal globus pallidus
KW - local field potentials
UR - http://www.scopus.com/inward/record.url?scp=85104112990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104112990&partnerID=8YFLogxK
U2 - 10.1002/mds.28566
DO - 10.1002/mds.28566
M3 - Article
C2 - 33847406
AN - SCOPUS:85104112990
SN - 0885-3185
VL - 36
SP - 1332
EP - 1341
JO - Movement Disorders
JF - Movement Disorders
IS - 6
ER -